Dissemination Policy Section
SPIRIT 2025 includes dissemination-policy reporting for trial protocols, covering how results will be communicated and relevant publication or authorship arrangements. Dissemination obligations vary by registry, funder, sponsor, journal, ethics approval, participant commitments, and jurisdiction. Do not promise a particular outlet or unrestricted disclosure when binding constraints apply.
A Dissemination Policy section explains how trial findings are intended to be communicated to scientific, participant, stakeholder, or public audiences and records applicable publication or authorship arrangements.
Key details
Important caveats
Scope Boundary
Dissemination obligations vary by registry, funder, sponsor, journal, ethics approval, participant commitments, and jurisdiction. Do not promise a particular outlet or unrestricted disclosure when binding constraints apply.
Further guidance
Content
Describe intended result dissemination routes, communication to participants or relevant communities when planned, publication responsibilities, and material authorship or sponsor-review arrangements where applicable.
Purpose
Make the planned routes and responsibilities for communicating trial results transparent.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- SPIRIT 2025 explanation and elaboration: updated guideline for protocols of randomised trials (opens in a new tab)BMJ / SPIRIT-CONSORT Group · Primary SPIRIT 2025 explanation and elaboration for trial protocols, including trial monitoring and data monitoring committee roles and reporting structure.